248 related articles for article (PubMed ID: 28721629)
21. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
22. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
24. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
25. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model.
Wang YD; Hu Y; Huang J; Zhang L; Sun CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1069-72. PubMed ID: 18928597
[TBL] [Abstract][Full Text] [Related]
27. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
Purushothaman A; Toole BP
J Biol Chem; 2014 Feb; 289(9):5499-509. PubMed ID: 24403068
[TBL] [Abstract][Full Text] [Related]
28. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
[TBL] [Abstract][Full Text] [Related]
29. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW; Stringer BW; Al-Ejeh F; Ting MJ; Wilson J; Ensbey KS; Jamieson PR; Bruce ZC; Lim YC; Offenhäuser C; Charmsaz S; Cooper LT; Ellacott JK; Harding A; Leveque L; Inglis P; Allan S; Walker DG; Lackmann M; Osborne G; Khanna KK; Reynolds BA; Lickliter JD; Boyd AW
Cancer Cell; 2013 Feb; 23(2):238-48. PubMed ID: 23410976
[TBL] [Abstract][Full Text] [Related]
30. The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.
Chen R; Zhao H; Wu D; Zhao C; Zhao W; Zhou X
Oncotarget; 2016 Nov; 7(45):73101-73113. PubMed ID: 27683032
[TBL] [Abstract][Full Text] [Related]
31. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
33. The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
Wang Q; Wang S; Sun SQ; Cheng ZH; Zhang Y; Chen G; Gu M; Yao HJ; Wang Z; Zhou J; Peng YB; Xu MX; Zhang K; Sun XW
Cancer Biomark; 2016; 16(1):1-9. PubMed ID: 26484606
[TBL] [Abstract][Full Text] [Related]
34. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
35. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
Neri P; Tassone P; Shammas M; Yasui H; Schipani E; Batchu RB; Blotta S; Prabhala R; Catley L; Hamasaki M; Hideshima T; Chauhan D; Jacob GS; Picker D; Venuta S; Anderson KC; Munshi NC
Leukemia; 2007 Dec; 21(12):2519-26. PubMed ID: 17882285
[TBL] [Abstract][Full Text] [Related]
36. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
[TBL] [Abstract][Full Text] [Related]
37. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
38. EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways.
Li M; Yang C; Liu X; Yuan L; Zhang F; Wang M; Miao D; Gu X; Jiang S; Cui B; Tong J; Yu Z
Cancer Lett; 2016 Dec; 383(2):195-203. PubMed ID: 27721017
[TBL] [Abstract][Full Text] [Related]
39. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
40. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.
Talia M; Cirillo F; Spinelli A; Zicarelli A; Scordamaglia D; Muglia L; De Rosis S; Rigiracciolo DC; Filippelli G; Perrotta ID; Davoli M; De Rosa R; Macirella R; Brunelli E; Miglietta AM; Nardo B; Tosoni D; Pece S; De Francesco EM; Belfiore A; Maggiolini M; Lappano R
J Exp Clin Cancer Res; 2023 Jul; 42(1):164. PubMed ID: 37434266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
